Powered by ZigaForm version 3.9.8.8

Public Alert No. 029/2022 – Public Alert On Recall Of Pink Pussycat Capsules By F&S Medical Supply Due To The Presence Of Undeclared Sildenafil

May 17, 2022,

The National Agency for Food and Drug Administration and Control (NAFDAC) is notifying the general public that F&S Medical Supply, dba Pink Toyz is recalling one lot of Pink Pussycat 3000 mg capsules. This is because FDA analysis has found the product Pink Pussycat to be tainted with sildenafil.

Sildenafil is an ingredient known as a phosphodiesterase (PDE-5) inhibitor found in an FDA approved product for the treatment of male erectile dysfunction. The presence of sildenafil in Pink Pussycat capsules renders the product an unapproved drug for which the safety and efficacy has not been established and, therefore, subject to recall.

The implicated products are marketed as dietary supplements for male sexual enhancement and sold online (Amazon at www.amazon.com).

Possible Risk

The undeclared tadalafil or sildenafil ingredient may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels that may be life threatening. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

Consumers with underlying medical issues who take Pink Pussycat with undeclared tadalafil may experience serious health risks as the PDE-5 inhibitors may interact with nitrates found in some of their prescription drugs.

Product Details

The details of the affected product are as follows;

The product is marketed as a dietary supplement for male sexual enhancement and is packaged in 1 count blister pack.

Recalling Company Product Name Lot Number Expiry date UPC
F&S Medical Supply, dba Pink Toyz, Chatsworth, California, Pink Pussycat 3000 mg capsules  2009066 09/2023 8 91875 00462 6

Product Photo

NAFDAC implores consumers to stop the purchase and use of these products.

Members of the public in possession of the implicated products are implored to stop the sale or use and handover products to the nearest NAFDAC office.

Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using any of the implicated product.

NAFDAC encourages healthcare professionals, consumers and patients to report adverse events related to the use of the products to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLLS FREE from all networks) or via pharmacovigilance@nafdac.gov.ng, E- reporting platforms available on the NAFDAC website or via the Med- safety application available for download on android and IOS stores.

NAFDAC……..Customer-focused, Agency-minded!!!

Signed Management

Was this post helpful?